Key Biologics and Astarte Biologics Rebrand as Cellero and Announce Completion of Phase One of $50 Million Multi-Year Expansion Plan

New brand and expansion reflect the company’s mission to support the development and delivery of tomorrow’s treatments and cures. MEMPHIS, TN and BOTHELL, WA – May 12, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today…

Read more

Unlocking Cures in the New Decade

Welcome customers, partners, and colleagues to the new Cellero website! On behalf of Key Biologics and Astarte Biologics, I’d like to introduce you to our new brand. My name is Jeff Allen, CEO of Cellero. Over the past two years, the Key Biologics and Astarte Biologics teams have been working tirelessly to combine two valued,…

Read more

Key Biologics Joins the Fight Against COVID-19

Launches new program to supply blood products from COVID-19 convalescent donors LOWELL, MA and MEMPHIS, TN – April 29, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today announced the launch of an IRB-approved initiative to…

Read more
COVID-19 blood research

COVID-19 Research at Key Bio: Convalesced Patients – Plasma & Immune Cells

Recovered patients carrying SARS-CoV-2 antibodies are being collected under Key Biologics newest IRB-Approved protocol to help drive therapeutic agent & vaccine development. Responding to the FDA’s call-to-action for convalesced plasma & other blood products collection, and to meet mounting requests from institutional & biopharmaceutical researchers in need of premium cells, Key Bio’s COVID-19 protocol is active in…

Read more

Coronavirus (COVID-19) Readiness

Key Biologics (A Cellero Company) is open and maintaining normal operations. To ensure that we can maintain normal operations as the spread of COVID-19 continues, we have activated our business continuity plans. Our management teams are focused on overseeing our response to the evolving situation. COVID-19 has not impacted Key Biologics’ ability to deliver any…

Read more

Donor Screening and Care at Key Biologics

Assessing an individual’s eligibility to safely donate blood products has always been and remains our highest priority. To accomplish this, we use a several stepped process, learn more about our process below. Key Biologics (A Cellero Company) has transitioned over the past two plus decades from a department within an FDA-registered community blood center providing…

Read more